Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Toripalimab Plus Chemotherapy for Resectable Stage II-IIIB Non-squamous NSCLC With EGFR Mutation
NCT05962021Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Aug 2023
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of toripalimab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 cohorts), sponsored by Peking University People's Hospital. Primary endpoint: Pathologic Complete Response Rate. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05962021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05962021.